1. Hardy JD, Webb WR, Dalton ML Jr, Walker GR Jr. Lung homotransplantations in man. JAMA. 1963; 186: 1065.
2. Calne RY, White DJ, Thiru S, Evans DB, McMaster P, Dunn DC, Craddock GN, Pentolow BD, Rolles K. Cyclosporin A in patients receiving renal allografts from cadaver donors. Lancet. 1978; 2(8104-5): 1323-1327
3. Toronto Lung Transplant Group. Unilateral lung transplantation for pulmonary fibrosis. N Engl J Med. 1986; 314(18): 1140-1145
4. Cooper JD, Patterson GA, Grossman R, Maurer J. Double-lung transplant for advanced chronic obstructive lung disease. Am Rev Respir Dis. 1989; 139(2): 303- 307
5. Chambers DC, Yusen RD, Cherikh WS, Goldfarb SB, Kucheryavaya AY, Khusch K, Levvey BJ, Lund LH, Mieser B, Rossano JW, Stehik J; Internationla Society for Heart and Lung Transplantation. The registry of the International Society for Heart and Lung Transplantation: thirty-fourth adult lung and heart-lung transplantation report-2017: focus theme: allograft ischemic time. J Herat Lung Transplant. 2017; 36(10): 1047-1059
6. 三好新一郎. 本邦初の脳死肺移植. 今日の移植. 2000; 13: 412-417
7. 松村輔二, 岡田克典, 佐渡哲, 藤村重文, 近藤丘. 本邦初の脳死肺移植. 今日の移植. 2000; 13: 418-425
8. 小泉知展, 山本洋, 久保惠嗣. 本邦初の生体肺移植患者の臨床経過–気管支拡張症 (primary ciliary dyskinesia)症例–. 呼吸. 2003; 22: 387
9. 日本肺および心肺移植研究会ホームページ：レジストリーレポート http://www2.idac.tohoku.ac.jp/dep/surg/shinpai/pg185.html (6/21/2018)
10. Weil D, Benden C, Corris PA, Dark JH, Davis RD, Keshavjee S, Lederer DJ, Mulligan MJ, Patterson GA, Singer LG, Snell GI, Verleden GM, Zamora MR, Glanville AR A consensus document for the selection of lung transplant candidates: 2014-an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2015; 34(1): 1-15.
11. Nathan SD. Lung transplantation: disease-specific considerations for referral. Chest. 2005; 127(3): 1006-1016
12. Tuppin MP, Paratz JD, Chang AT, Seale HE, Kermeeen FD, McNeil KD, Hopkins PM. Predictive utility of the 6-minute walk distance on survival in patients awaiting lung transplantation. J Heart Lung Transplant. 2008; 27(7): 729-734.
13. ISHLT ホームページ http://www.ishlt.org/ (6/21/2018)
14. Santacruz JF, Mehta AC. Airway complications and management after lung transplantation: ischemia, dehiscence, and stenosis. Proc Am Thorac Soc. 2009; 6(1):79-93
15. Van De Wauwer C, Van Raemdonck D, Verleden GM, Dupont L, De Leyn P, Coosemans W, Nafteux P, Lerut T. Risk factors for airway complications within the first year after lung transplantation. Eur J Cardiothorac Surg. 2007; 31(4): 703-710
16. Machuzak M, SantacruZ JF, Gildea T, Murthy SC. Airway complications after lung transplantation. Thorac Surg Clin. 2015; 25(1): 55-75
17. Anaya-Ayala JE, Loebe M, Davies MG. Endovascular management of early lung transplant-related anastomotic pulmonary artery stenosis. J Vasc Interv Radiol. 2015; 26(6): 878-882
18. Miyaji K, Nakamura K, Mauro T, Morita H, Saito H, Emori T, Goto K, Date H, Ohe T. Effect of a kink in unilateral pulmonary artery anastomosis on velocities of blood flow through bilateral pulmonary vein anastomosis in living-donor lobar lung transplantation. J Am Soc Echocardiogr. 2004; 17(9): 998-999
19. Chen F, Tazaki J, Shibata T, Miwa S, Yamazaki K, Ishii H, Shoij T, Fujinaga T, Bando T, Date H. Stent angioplasty for a kink in the pulmonary artery anastomosis soon after living-donor lung transplantation. Ann Thorac Surg. 2011; 92(5): 105- 106
20. Uhlmann EJ, Dunitz JM, Fiol ME. Pulmonary vein thrombosis after lung transplantation presenting as stroke. J Heart Lung Transplant. 2009; 28(2): 209-210
21. Schulman LL, Anandarangam T, Leibowitz DW, Ditullio MR, McGregor CC, Galantowicz ME, Homma S. Four-year prospective study of pulmonary venous thrombosis after lung transplantation. J Am Soc Echocardiogr. 2001; 14(8): 806-812
22. Leibowitz DW, Smith CR, Michler RE, Ginsburg M, Schulman LL, McGregor CC, Li Mandori G, Weslow RG, Di Tullio MR, Homma S. Incidence of pulmonary vein complications after lung transplantation: a prospective transesophageal echocardiographic study. J Am Coll Cardiol. 1994; 24(3): 671-675
23. Maziak DE, Maurer JR, Kesten S. Diaphragmatic paralysis: a complication of lung transplantation. Ann Thorac Surg. 1996; 61(1): 170-173
24. Boehler A, Speich R, Russi EW, Weder W. Lung transplantation for lymphangioleiomyomatosis. N Engl J Med. 1996; 335(17): 1275-1280
25. Christie JD, Van Raemodonck D, de Perrot M, Barr M, Keshavjee S, Acrasoy S, Orens J; ISHLT Working Group on Primary Lung Graft Dysfunction. Report of the ISHLT Working Group on Primary Lung Graft Dysfunction part I: introduction and methods. J Heart Lung Transplant. 2005; 24(10): 1451-1453
26. Christie JD, Bavaria JE, Palevsky HI, Litzky L, Blumenthal NP, Kaiser LR, Kotloff RM. Primary graft failure following lung transplantation. Chest. 1998; 114(1): 51-60
27. de Perrot M, Liu M, Waddell TK, Keshavjee S. Ischemia-reperfusion-induced lung injury. Am J Respir Crit Care Med. 2003; 167(4): 490-511
28. Christie JD, Carby M, Bag R, Corris P, Hertz M, Weill D; ISHLT Working Group on Primary Lung Graft Dysfunction. Report of the ISHLT Working Group on Primary Lung Graft Dysfunction part II: definition. A consensus statement of the Intenational Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2005; 24(10): 1454-1459
29. Oto T, Griffiths AP, Levvey BJ, Pilcher DV, Williams TJ, Snell GI. Definitions of primary graft dysfunction after lung transplantation: differences between bilateral and single lung transplantation. J Thorac Cardiovasc Surg. 2006; 132(1): 140-147
30. Martinu T, Chen DF, Palmer SM. Acute rejection and humoral sensitization in lung transplant recipients. Proc Am Thorac Soc. 2009; 6(1): 54-65
31. Martinu T, Pavlisko EN, Chen DF, Palmer SM. Acute allograft rejection: cellular and humoral processes. Clin Chest Med. 2011; 32(2): 295-310
32. Yusen RD, Edwards LB, Kucheryavaya AY, Benden C, Dipchand AI, Goldfarb SB, Levvey BJ, Lund LH, Meiser B, Rossano JW, Stehik J. The registry of the International Society for Heart and Lung Transplantation: thirty-second official adult lung and heart-lung transplantation report-2015: focus theme: early graft failure. J Herat Lung Transplant. 2015; 34(10): 1264-1277
33. De Vito Dabbs A, Hoffman LA, Iacono AT, Zullo TG, McCurry KR, Dauber JH. Are symptom reports useful for differentiating between acute and pulmonary infection after lung transplantation. Heart Lung. 2004; 33(6): 372-380
34. Stewart S, Fishbein MC, Snell GI, Berry GJ, Boehler A, Burke MM, Glanville A, Gould FK, Magro C, Marboe CC, McNeil KD, Reed EF, Reinsmoen NL, Scott JP, Studer SM, Tazelaar HD, Wallwork JL, Westall G, Zamore MR, Zeevi A, Yousem SA. Revision of the 1990 working formulation for the standardization of the nomenclature in the diagnosis of lung rejection. J Heart Lung Transplant. 2007; 26(12): 1229-1242
35. Girnita DM, Webber SA, Zeevi A. Clinical impact of cytokine and growth factor genetic polymorphisms in thoracic organ transplantation. Clin Lab Med. 2008; 28(3): 423-40
36. Zheng HX, Zeevi A, McCurry K, Schuetz E, Webber S, Ristich J, Zhang J, Iacono A, Dauber J, McDade K, Zaldonis D, Lamba J, Burckart GJ. The impact of pharmacogenomic factors on acute persistent rejection in adult lung transplant patients. Transpl Immunol. 2005; 14(1): 37-42
37. Colobran R, Casamitjana N, Roman A, Faner R, Pedrosa E, Arostegui JI, Pujol- Borrell R, Juan M, Palou E. Copy number variation in the CCL4L gene is associated with susceptibility to acute rejection in lung transplantation. Genes Immun. 2009; 10(3): 254-9
38. Palmer SM, Burch LH, Trindade AJ, Davis RD, Herczyk WF, Reinsmoen NL, Schwartz DA. Innate immunity influences long-term outcomes after human lung transplant. Am J Respir Crit Care Med. 2005; 171(7): 780-5
39. Levine SM, Transplant/Immunology Network of the American College of Chest Physicians. A survey of clinical practice of lung transplantation in North America. Chest. 2004; 125(4): 1224-38
40. Glanville AR. Bronschopic monitoring after lung transplantation. Semin Respir Crit Care Med. 2010; 31(2): 208-221
41. Verleden GM, Raghu G, Meyer KC, Glanville AR, Corris P. A new classification system for chronic lung allograft dysfunction. J Heart Lung Transplant. 2014; 33(2): 127-33
42. Cooper JD, Billingham M, Egan T, Hertz MI, Higenbottam T, Lynch J, Mauer J, Paradis I, Patterson GA, Smith C. A working formulation for the standardization of nomenclature and for clinical staging of chronic dysfunction in lung allografts. International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 1993; 12(5): 713-716
43. Estenne M, Maurer JR, Boehler A, Egan JJ, Frost A, Hertz M, Mallory GB, Snell GI, Yousem S. Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria. J Heart Lung Transplant. 2002; 21(3): 297-310
44. Keller CA, Cagle PT, Brown RW, Noon G, Frost AE. Bronchiolitis obliterans in recipients of single, double, and heart-lung transplantation. Chest. 1995; 107(4): 973-980
45. Chalermskulrat W, Neuringer IP, Schmitz JL, Catellier DJ, Gurka MJ, Randell SH, Aris RM. Human leukocyte antigen mismatches predispose to the severity of bronchiolitis obliterans syndrome after lung transplantation. Chest. 2003; 123(6): 1825-1831
46. Sumpter TL, Wilkes DS. Role of autoimmunity in organ allograft rejection: a focus on immunity to type V collagen in the pathogenesis of lung transplant rejection. Am J Physiol Lung Cell Mol Physiol. 2004; 286(6): L1129-1139
47. Estenne M, Maurer JR, Boehler A, Egan JJ, Frost A, Hertz M, Mallory GB, Snell GI, Yousem S. Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria. J Heart Lung Transplant. 2002; 21(3): 297-310
48. Xu X, Golden JA, Dolganov G, Jones KD, Donnelly S, Weaver T, Caughey GH. Transcript signatures of lymphocytic bronchitis in lung allograft biopsy specimens. J Heart Lung Transplant. 2005; 24(8): 1055-1066
49. Novick RJ, Stitt LW, Al-Kattan K, Klepetko W, Schäfers HJ, Duchatelle JP, Khaghani A, Hardesty RL, Patterson GA, Yacoub MH. Pulmonary retransplantation: predictors of graft function and survival in 230 patients. Pulmonary Retransplant Registry. Ann Thorac Surg. 1998; 65(1): 227-234
50. Whitford H, Walters EH, Levvey B, Kotsimbos T, Orsida B, Ward C, Pais M, Reid S, Williams T, Snell G. Addition of inhaled corticosteroids to systemic immunosuppression after lung transplantation: a double-blind, placebo-controlled trial. Transplantation. 2002; 73(11): 1793-1799
51. Vos R, Vanaudenaerde BM, Verleden SE, De Vleeschauwer SI, Willems- Widyastuti A, Van Raemdonck DE, Schoonis A, Nawrot TS, Dupont LJ, Verleden GM. A randomised controlled trial of azithromycin to prevent chronic rejection after lung transplantation. Eur Respir J. 2011; 37(1): 164-172
52. Sato M, Waddell TK, Wagnetz U, Roberts HC, Hwang DM, Haroon A, Wagnetz D, Chaparro C, Singer LG, Hutcheon MA, Keshavjee S. Restrictive allograft syndrome (RAS): a novel form of chronic lung allograft dysfunction. J Heart Lung Transplant. 2011; 30(7): 735-742
53. Verleden SE, Todd JL, Sato M, Palmer SM, Martinu T, Pavilsko EN, Vos R, Neyrinck A, Van Raemdonck D, Saito T, Oishi H, Keshavjee S, Greer M, Warnecke G, Gottlieb J, Haverich A. Impact of CLAD phenotype on survival after lung retransplantation: a multicenter study. Am J Transplant. 2015; 15(8): 2223-2230
54. Lama VN, Belperio JA, Christie JD, El-Chemaly S, Fishbein MC, Gelman AE, Hancock WW, Keshavjee S, Kreisel D, Laubach VE, Looney MR, McDyer JF, Mohanakumar T, Shilling RA, Panoskaltsis-Mortari A, Wilkes DS, Eu JP, Nicolls MR. Models of Lung Transplant Research: a consensus statement from the National Heart, Lung, and Blood Institute workshop. JCI Insight. [Epub ahead of print]
55. Okazaki M1, Krupnick AS, Kornfeld CG, Lai JM, Ritter JH, Richardson SB, Huang HJ, Das NA, Patterson GA, Gelman AE, Kreisel D. A mouse model of orthotopic vascularized aerated lung transplantation. Am J Transplant. 2007; 7(6): 1672-1679
56. Prop J, Tazelaar HD, Billimgham ME. Rejection of combined heart-lung transplantations in rats. Function and pathology. Am J Pathol. 1987; 127(1): 97-105
57. Hertz MI, Jessurun J, King MB, Savik SK, Murray JJ. Reproduction of the obliterative bronchiolitis lesion after heterotopic transplantation of mouse airways. Am J Pathol. 1993; 142(6): 1945-1951
58. Neuringer IP, Mannon RB, Coffman TM, Parsons M, Burns K, Yankaskas JR, Aris RM. Immune cells in a mouse airway model of obliterative bronchiolitis. Am J Respir Cell Mol Biol. 1998; 19(3): 379-386
59. Minamoto K, Harada H, Lama VN, Fedarau MA, Pinsky DJ. Reciprocal regulation of airway rejection by the inducible gasforming enzymes heme oxygenase and nitric oxide synthase. J Exp Med. 2005; 202(2): 283-294
60. Sato M, Hirayama S, Hwang DM, Lara-Guerra H, Wagnetz D, Waddell TK, Liu M, Keshavjee S. The role of intrapulmonary de novo lymphoid tissue in obliterative bronchiolitis after lung transplantation. J Immunol. 2009; 182(11): 7307-7316
61. Gelman AE, Li W, Richardson SB, Zinselmeyer BH, Lai J, Okazaki M, Kornfeld CG, Kreisel FH, Sugimoto S, Tietjens JR, Dempster J, Patterson GA, Krupnick AS, Miller MJ, Kreisel D. Cutting edge: Acute lung allograft rejection is independent of secondary lymphoid organs. J Immunol. 2009; 182(7): 3969-3973
62. Li W, Sugimoto S, Lai J, Patterson GA, Gelman AE, Krupnick AS, Kreisel D. Orthotopic vascularized right lung transplantation in the mouse. J Thorac Cardiovasc Surg. 2010; 139(6): 1637-1643
63. Li W, Goldstein DR, Bribriesco AC, Nava RG, Spahn JH, Wang X, Gelman AE, Krupnick AS, Kreisel D. Surgical technique for lung retransplantation in the mouse. J Thorac Dis. 2013; 5(3): 321-325
64. Bretcher PA. A two-step, two-signal model for the primary actuvation of precursor helper T cells. Proc Natl Acad Sci U S A. 1999; 96(1): 185-190
65. Curtsinger JM, Mescher MF. Inflammatory cytokines as a third signal for T cell activation. Curr Opin Immunol. 2010; 22(3): 333-340
66. Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co- inhibition. Nat Rev Immunol. 2013; 13(4): 227-242
67. Isobe M, Yagita H, Okumura K, Ihara A. Specific acceptance of cardiac allograft after treatment with antibodies to ICAM-1 and LFA-1. Science. 1992; 255(5048): 1125-1127
68. Fife BT, Bluestone JA. Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. Immunol Rev. 2008; 224: 166-182
69. Riella LV, Paterson AM, Sharpe AH, Chandraker A. Role of the PD-1 pathway in the immune response. Am J Transplant. 2012; 12(10): 2575-2587
70. Linsley PS, Brady W, Urnes M, Grosmaire LS, Damle NK, Ledbetter JA. CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med. 1991; 174(3): 561- 569
71. Ishida Y, Agata Y, Shibahara K, Honji T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 1992; 11(11): 3887-3895
72. Agata Y, Kawasaki A, Nishimura H, Ishida Y, Tsubata T, Yagita H, Honjo T. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol. 1996; 8(5): 765-772
73. Liang SC, Latchman YE, Buhlmann JE, Tomczak MF, Horwitz BH, Freeman GJ, Sharpe AH. Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses. Eur J Immunol. 2003; 33(10): 2706-2716
74. Dong H, Zhu G, Tamada K, Chen L. B7-H1, a third member of the B7 family, co- stimulates T-cell proliferation and interleukin-10 secretion. Nat Med. 1999; 5(12): 1365-1369
75. Lee SJ, Jang BC, Lee SW, Yang YI, Shuh SI, Park YM, Oh S, Shin JG, Yao S, Chen L, Choi IH. Interferon regulatory factor-1 is prerequisite to the constitutive expression and IFN-gamma-induced upregulation of B7-H1 (CD274). FEBS Lett. 2006; 580(3): 755-762
76. Freeman GJ, Wherry EJ, Ahmed R, Sharpe AH. Reinvigorating exhausted HIV- specific T cells via PD-1-PD-1 ligand blockade. J Exp Med. 2006; 203(10): 2223-2227
77. Kinter AL, Godbout EJ, McNally JP, Sereti I, Roby GA, O’Shea MA, Fauci AS. The common gamma-chain cytokines IL-2, IL-7, IL-15, and IL-21 induce the expression of programmed death-1 and its ligands. J Immunol. 2008; 181(10): 6738- 6746
78. Oestreich KJ, Yoon H, Ahmed R, Boss JM. NFATc1 regulates PD-1 expression upon T cell activation. J Immunol. 2008; 181(7): 4832-4839
79. Eppihimer MJ, Gunn J, Freeman GJ, Greenfield EA, Chermova T, Erickson J, Leonard JP. Expression and regulation of the PD-L1 immunohibitory molecule on microvascular endothelia cells. Microcirculation. 2002; 9(2): 133-145
80. Zhong X, Tumang J, Gao W, Bai C, Rothstein T. PD-L2 expression extends beyond dendritic cells/ macrophages to B1 cells enriched for V(H)11/V(H)12 and phosphatidylcholiune binding. Eur J Immunol. 2007; 37(9): 2405-2410
81. Wang J, Yoshida T, Nakaki F, Hirai H, Okazaki T, Honjo T. Establishment of NOD- Pdcd 1-/- mice as an efficient animal model of type I diabetes. Proc Natl Acad Sci U S A. 2005; 102(33): 11823-11828
82. Nishimura H, Nose M, Hirai H, Minato N, Honjo T. Development of lupus-like autoimmune disease by disruption of the PD-1 gene encoding an ITIM motif- carrying immunoreceptor. Immunity. 1999; 11(2): 141-151
83. Nishimura H, Okazaki T, Tanaka Y, Nakatani K, Hara M, Matsumori A, Sasayama S, Mizoguchi A, Hirai H, Minato N, Honjo T. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science. 2001; 291(5502): 319-322
84. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, Barlesi F, Kohlhäufl M, Arrieta O, Burgio MA, Fayette J, Lena H, Poddubskaya E, Gerber DE, Gettinger SN, Rudin CM, Rizvi N, Crinò L, Blumenschein GR Jr, Antonia SJ, Dorange C, Harbison CT, Graf Finckenstein F, Brahmer JR. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small- Cell Lung Cancer. N Engl J Med. 2015; 373(17): 1627-39
85. Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E, Waterhouse D, Ready N, Gainor J, Arén Frontera O, Havel L, Steins M, Garassino MC, Aerts JG, Domine M, Paz-Ares L, Reck M, Baudelet C, Harbison CT, Lestini B, Spigel DR. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med. 2015; 373(2): 123-35
86. Herbst RS, Baas P, Kim DW, Felip E, Pérez-Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, Majem M, Fidler MJ, de Castro G Jr, Garrido M, Lubiniecki GM, Shentu Y, Im E, Dolled-Filhart M, Garon EB. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016; 387(10027): 1540-50
87. Sheng J, Fang W, Yu J, Chen N, Zhan J, Ma Y, Yang Y, Huang Y, Zhao H, Zhang L. Expression of programmed death ligand-1 on tumor cells varies pre and post chemotherapy in non-small cell lung cancer. Sci Rep. 2016; 6: 20090
88. Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, Gadgeel SM, Hida T, Kowalski DM, Dols MC, Cortinovis DL, Leach J, Polikoff J, Barrios C, Kabbinavar F, Frontera OA, De Marinis F, Turna H, Lee JS, Ballinger M, Kowanetz M, He P, Chen DS, Sandler A, Gandara DR; OAK Study Group. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017; 389(10066): 255-265
89. Tanaka K, Albin MJ, Yuan X, Yamamura K, Habicht A, Murayama T, Grimm M, Waaga AM, Ueno T, Padera RF, Yagita H, Azuma M, Shin T, Blazar BR, Rothestein DM, Sayegh MH, Najaflan N. PD-L1 is required for peripheral transplantation tolerance and protection from chronic allograft rejection. J Immunol. 2007; 179(8): 5204- 5210
90. Morita M, Fujino M, Jiang G, Kitazawa Y, Xie L, Azuma M, Yagita H, Nagano S, Sugioka A, Kurosawa Y, Takahara S, Fung J, Qian S, Lu L, Li XK. PD-1/B7-H1 interaction contribute to the spontaneous acceptance of mouse liver allograft. Am J Transplant. 2010; 10(1): 40-46
91. Jameson SC, Masopust D. Diversity in T cell memory: An embarrassment of riches. Immunity. 2009; 31(6): 859-871
92. Krupnick AS, Lin X, Li W, Higashikubo R, Zinselmeyer BH, Hartzler H, Toth K, Ritter JH, Berezin MY, Wang ST, Miller MJ, Gelman AE, Kreisel D. Central memory CD8+ T lymphocytes mediate lung allograft acceptance. J Clin Invest. 2014; 124(3): 1130-1143
93. Zinselmeyer BH, Heydari S, Sacristan C, Nayak D, Cammer M, Herz J, Cheng X, Davis SJ, Dustin ML, McGavern DB. PD-1 promotes immune exhaustion by inducing antiviral T cell motility paralysis. J Exp Med. 2013; 210(4): 757-774
94. Fife BT, Pauken KE, Eagar TN, Obu T, Wu J, Tang Q, Azuma M, Krummel MF, Bluestone JA. Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal. Nat Immunol. 2009; 10(11): 1185-1192
95. Marzo AL, Yagita H, Lefrancois L. Cutting edge: migration to nonlymphoid tissues results in functional conversion of central to effector memory CD8 T cells. J Immunol. 2007; 179(1): 36-40
96. Charlton JJ, Chatzidakis I, Tsoukatou D, Boumpas DT, Garinis GA, Mamalaki C. Programmed death-1 shapes memory phenotype CD8 T cell subsets in a cell- intrinsic manner. J Immunol. 2013; 190(12): 6104-6114
97. Nava RG, Li W, Gelman AE, Krupnick AS, Miller MJ, Kreisel D. Two photon microscopy in pulmonary research. Semin Immunopathol. 2010; 32(3): 297-304
98. Wang L, Han R, and Hancock WW. Programmed cell death 1 (PD-1) and its ligand PD-L1 are required for allograft tolerance. Eur J Immunol. 2007; 37(10): 2983-2990
99. Koehn BH, Ford ML, Ferrer IR, Borom K, Gangappa S, Kirk AD, Larsen CP. PD-1-dependent mechanisms maintain peripheral tolerance of donor-reactive CD8+ T cells to transplanted tissue. J Immunol. 2008; 181(8): 5313-5322
100. Huster KM, Koffler M, Stemberger C, Schiemann M, Wagner H, Busch DH. Unidirectional development of CD8+ central memory T cells into protective Listeria- specific effector memory T cells. Eur J Immunol. 2006; 36(6): 1453-1464
101. Bouneaud C, Garcia Z, Kourilsky P, Pannetier C. Lineage relationships, homeostasis, and recall capacities of central- and effector-memory CD8 T cells in vivo. J Exp Med. 2005; 201(4): 579-590
102. Mousavi SF, Soroosh P, Takahashi T, Yoshikai Y, Shen H, Lefrancois L, Borst J, Sugamura K, Ishii N. OX40 costimulatory signals potentiate the memory commitment of effector CD8+ T cells. J Immunol. 2008; 181(9): 5990-6001
103. Benvenuti F, Lagaudriere-Gesbert C, Grandjean I, Jancic C, Hivroz C, Trautmann A, Lantz O, Amigorena S. Dendritic cell maturation controls adhesion, synapse formation, and the duration of the interactions with naive T lymphocytes. J Immunol. 2004; 172(1): 292-301
104. Scholer A, Hugues S, Boissonnas A, Fetler L, Amigorena S. Intercellular adhesion molecule-1-dependent stable interactions between T cells and dendritic cells determine CD8+ T cell memory. Immunity. 2008; 28(2): 258-270
論文の公開元へ
